Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BHADRESH PATEL

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1003913252
CMS profile
226942
Location
BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$676.49

44 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $662.60 43
Education $13.89 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BHADRESH PATEL

NPI 1003913252 · CMS profile ID 226942

Allopathic & Osteopathic Physicians / Internal Medicine

BEVERLY HILLS, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1003913252?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1003913252?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1003913252?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
BHADRESH PATEL, NPI 1003913252, CMS profile ID 226942, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–44 of 44 matching records. This page contains 44 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1003913252?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

44 matching records · $676.49 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 44 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–44 of 44.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Esperion Therapeutics, Inc. $20.7511/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 947275721 CMS
Lilly USA, LLC $13.1510/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917910123 CMS
ABBVIE INC. $11.0910/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325297 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $23.5609/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887481795 CMS
ABBVIE INC. $8.9909/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325295 CMS
ABBVIE INC. $14.7208/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325293 CMS
Biohaven Pharmaceutical Holding Company Ltd. $24.0008/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923696277 CMS
PFIZER INC. $13.3408/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949207047 CMS
Lilly USA, LLC $13.1608/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 917906063 CMS
Biohaven Pharmaceutical Holding Company Ltd. $15.8307/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923696275 CMS
GlaxoSmithKline, LLC. $12.8206/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945004151 CMS
Novo Nordisk Inc $20.7806/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899122243 CMS
Novo Nordisk Inc $14.3406/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899122233 CMS
Amgen Inc. $22.4506/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939569429 CMS
Nestle HealthCare Nutrition Inc. $19.4406/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 902791637 CMS
ABBVIE INC. $19.1306/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325291 CMS
Janssen Pharmaceuticals, Inc $13.7105/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885902153 CMS
Amgen Inc. $13.6105/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939569427 CMS
Amgen Inc. $13.8905/05/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940067321 CMS
ABBVIE INC. $8.0504/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325289 CMS
Novartis Pharmaceuticals Corporation $20.2604/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894207363 CMS
Novo Nordisk Inc $18.5504/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899076513 CMS
ABBVIE INC. $7.4504/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325287 CMS
Astellas Pharma US Inc $15.4204/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940163561 CMS
Janssen Pharmaceuticals, Inc $12.7204/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885902141 CMS
ABBVIE INC. $3.2504/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325285 CMS
GlaxoSmithKline, LLC. $22.5004/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945004155 CMS
ABBVIE INC. $8.9203/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325283 CMS
Novo Nordisk Inc $19.6103/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899076523 CMS
Janssen Pharmaceuticals, Inc $14.9703/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885902135 CMS
ABBVIE INC. $13.4703/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325281 CMS
ABBVIE INC. $21.3403/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325279 CMS
Janssen Pharmaceuticals, Inc $13.8302/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885902147 CMS
Novo Nordisk Inc $24.4102/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899459673 CMS
SANOFI-AVENTIS U.S. LLC $16.0102/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938840835 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.9502/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887481797 CMS
ABBVIE INC. $15.3302/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325277 CMS
ABBVIE INC. $10.6102/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325275 CMS
Amgen Inc. $15.4201/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939569431 CMS
Astellas Pharma US Inc $12.7401/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940106939 CMS
Janssen Pharmaceuticals, Inc $14.1401/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885902159 CMS
ABBVIE INC. $12.9601/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325273 CMS
GlaxoSmithKline, LLC. $18.2101/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945004153 CMS
ABBVIE INC. $10.6101/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891325271 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,622.73 32
PY2020 $547.52 37
PY2021 $1,137.72 67
PY2022 $676.49 44
PY2023 $599.21 34
PY2024 $518.32 33
PY2025 $749.06 42

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,003.52 172
PY2024 Principal investigator $421,638.32 23
PY2023 Principal investigator $317,080.95 398
PY2022 Principal investigator $272,453.35 534
PY2020 Principal investigator $3,172.98 4
PY2019 Principal investigator $1,202.28 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

23 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $3,315.00 12/31/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192364
Principal investigator 1 ModernaTX, Inc. $50,296.72 12/19/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192360
Principal investigator 1 ModernaTX, Inc. $500.00 12/13/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192366
Principal investigator 1 ModernaTX, Inc. $195,402.27 11/27/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192354
Principal investigator 1 ModernaTX, Inc. $9,050.00 10/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192344
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/07/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192346
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/25/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192336
Principal investigator 1 ModernaTX, Inc. $9,000.00 09/12/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192330
Principal investigator 1 ModernaTX, Inc. $4,510.56 09/02/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192332
Principal investigator 1 ModernaTX, Inc. $598.68 08/29/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147192324
Principal investigator 1 ModernaTX, Inc. $10,162.01 08/01/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192320
Principal investigator 1 PFIZER INC. $2,073.60 07/03/2024 Non-covered Recipient Entity
Nature Coast Clinical Research
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 1130917679
Principal investigator 1 ModernaTX, Inc. $21,222.14 06/27/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192316
Principal investigator 1 ModernaTX, Inc. $6,996.94 05/02/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192310
Principal investigator 1 ModernaTX, Inc. $3,280.50 04/01/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192304
Principal investigator 1 ModernaTX, Inc. $5,550.00 03/28/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192294
Principal investigator 1 ModernaTX, Inc. $11,408.90 03/28/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192300
Principal investigator 1 ModernaTX, Inc. $51,094.28 03/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192292
Principal investigator 1 ModernaTX, Inc. $4,563.56 03/21/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192296
Principal investigator 1 ModernaTX, Inc. $6,695.00 03/20/2024 Non-covered Recipient Entity
Nature Coast Clinical Research, LLC - Crystal River
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147182845
Principal investigator 1 ModernaTX, Inc. $3,371.65 02/28/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147192284
Principal investigator 1 ModernaTX, Inc. $4,769.85 02/26/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192286
Principal investigator 1 ModernaTX, Inc. $15,276.66 01/16/2024 Non-covered Recipient Entity
NATURE COAST CLINICAL RESEARCH
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147192280